AMR is becoming a global healthcare burden, while India has opportunities in diagnostics, antibiotics, and vaccine innovation

Overview

This report focuses on the clinical, public health, and commercial impact of antimicrobial resistance (AMR). It argues that AMR is fundamentally an evolutionary selection problem under antibiotic exposure, leading to first-line antibiotic failure, treatment delays, longer hospital stays, increased ICU use, and higher mortality. The report identifies global policy incentives, diagnostics, vaccines, novel antibiotics, and endolysins as innovation directions, with a particular focus on India’s opportunities in diagnostics, policy, antibiotics, and vaccines.

Core views

The core views include: first, AMR has evolved from a medical issue into a healthcare payment, hospital operations, and macroeconomic issue; second, new antibiotics alone are insufficient to solve the problem, and antibiotic stewardship, rapid diagnostics, vaccine prevention, and payment incentives must work together; third, India’s high infection burden, low-cost demand, and domestic biopharma capabilities make it an important market for AMR innovation; fourth, novel antibiotics and bacterial vaccines still face high R&D risk, long development cycles, and commercialization constraints, and returns on investment need to be improved through policy and payment mechanisms.

Analysis framework

The report combines medical literature, Lancet GRAM 2024, estimates from the WHO and World Bank, policy case studies from the UK/Sweden/Japan, global and Indian product case studies, and valuation and rating tables for covered Indian pharmaceutical companies. Its logic starts from resistance mechanisms and extends to clinical pathways, healthcare costs, public policy, business models, and company asset mapping.

Methodology notes

• Medical MechanismResistance Mechanism Breakdown

  Acquired resistance and intrinsic resistance

  The report attributes AMR to increased antimicrobial use, inadequate implementation of treatment guidelines, and insufficient new drug supply, and further breaks this down into mechanisms such as β-lactamases, efflux pumps, target-site mutations, porin loss, and plasmid-mediated gene transfer.

• Policy and IncentivesAntibiotic Stewardship and Pull Incentives

  Prescribing-side incentives and manufacturer-side revenue guarantees in parallel

  Cases from the UK, Sweden, and Japan show that reducing unnecessary prescribing while providing revenue guarantees for critical antibiotics can both curb overuse and improve innovation supply.

• Commercialization FrameworkDiagnostics-to-Treatment Decision Chain

  Rapid testing converts pathogen and resistance information into treatment choices

  The report emphasizes that rapid PCR, multiplex PCR, and resistance gene testing not only provide lab results but also help physicians escalate, de-escalate, or avoid empiric broad-spectrum treatment.

• Health EconomicsVaccine Prevention Economics

  Reducing antibiotic use and resistance selection pressure by lowering infection at the source

  The AMR value of vaccines lies not in treating infection but in preventing infection, reducing prescriptions, and lowering transmission and hospitalization costs, so the payment logic depends on evidence of avoided disease and avoided complications.

• R&D RiskThe Antibiotic Innovation Return Paradox

  Society needs new antibiotics, but short treatment courses and reserve-use restrictions limit sales scale

  The report argues that novel antibiotic R&D has long development cycles and high failure risk, while antibiotic stewardship limits broad sales, creating a need for mechanisms such as subscription-based payment or revenue guarantees.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Roche Cobas / Cobas ePlex

  Global AMR diagnostic platform case

  Strengths

  Has an installed base, hospital relationships, and molecular diagnostic platforms, and can identify pathogens and resistance genes in about 90 minutes after a positive blood culture, making it suitable for ICU and inpatient infection pathways.

  Weaknesses

  More oriented toward hospitals and centralized settings, making it difficult to fully cover primary-care or low-cost decentralized demand.

  Comparison

  Compared with Visby Medical’s portable same-visit model, Roche places greater emphasis on scaled hospital integration and high-risk inpatient settings.

  Risks

  Hospital procurement, clinical workflow redesign, reimbursement acceptance, and panel coverage will affect penetration.

• Visby Medical

  Portable point-of-care PCR diagnostic case

  Strengths

  The platform is instrument-free and portable, and the report says it can deliver results within 30 minutes; its gonorrhea diagnostic program can identify both the pathogen and ciprofloxacin sensitivity.

  Weaknesses

  The company is privately held, and the report materials do not fully elaborate on its commercialization scale, channels, or long-term financing capacity.

  Comparison

  Compared with traditional culture and susceptibility workflows that take several days, the Visby model is closer to a same-visit treatment decision product.

  Risks

  Regulation, test accuracy, clinical adoption, and per-test cost are key uncertainties.

• Molbio Truenat

  India decentralized molecular diagnostics opportunity

  Strengths

  Portable and battery-powered, capable of detecting tuberculosis and rifampicin resistance within one hour; WHO recognizes Truenat MTB, MTB Plus, and MTB-RIF Dx as initial tests.

  Weaknesses

  Needs to balance low cost, high throughput, and operability in primary-care settings.

  Comparison

  Compared with centralized lab models, Truenat is better suited to markets such as India where laboratory infrastructure is constrained.

  Risks

  Primary-care deployment, quality control, consumables supply, and reimbursement/public procurement pricing will affect scale-up.

• HiMedia NG-Test CARBA-5

  Hospital carbapenem-resistance testing case

  Strengths

  Can detect five important carbapenemases—KPC, OXA-48-like, IMP, VIM, and NDM—from colonies in about 15 minutes.

  Weaknesses

  Its application scope is relatively narrow and depends on existing hospital laboratory culture workflows.

  Comparison

  Compared with full-pathogen multiplex PCR, its value is more concentrated on rapid confirmation of resistance mechanisms.

  Risks

  Testing scope, laboratory adoption, and shifts in resistance patterns may limit long-term value.

• Wockhardt Zaynich

  India original novel antibiotic case

  Strengths

  Approved by the US FDA in May 2026 for complicated UTI and pyelonephritis; Phase 3 ENHANCE-1 showed an 89.0% composite response, higher than meropenem’s 68.4%.

  Weaknesses

  The R&D cycle exceeded two decades, and commercial use as a reserve antibiotic may be constrained by antibiotic stewardship.

  Comparison

  Compared with global novel oral antibiotic categories represented by GSK’s Blujepa, Zaynich highlights a milestone in independent development and commercialization by an Indian company.

  Risks

  Commercial ramp-up, resistance evolution, drug safety, reimbursement access, and execution in regulated markets all require monitoring.

• Cipla ZEMDRI / plazomicin

  India reserve antibiotic toolbox

  Strengths

  Used for complicated UTI and pyelonephritis, with activity against certain multidrug-resistant Gram-negative bacteria, expanding treatment options for CRE-related urinary tract infections.

  Weaknesses

  Indications and usage scenarios are relatively concentrated, and aminoglycoside use requires attention to safety.

  Comparison

  Compared with Zaynich’s original Indian NCE narrative, plazomicin is more like an accessibility supplement for reserve antibiotics in the Indian market.

  Risks

  Usage restrictions, resistance, safety monitoring, and hospital access will affect utilization.

• Bharat Biotech

  India AMR vaccine platform case

  Strengths

  The report focuses on its vaccine pipeline for pre-surgical prevention of hospital-acquired infections, as well as Phase 3 candidates for TB, Shigella, Salmonella, and Chikungunya.

  Weaknesses

  Clinical endpoints for bacterial vaccines are complex, patient heterogeneity is high, and proving durability and efficacy is difficult.

  Comparison

  Compared with antibiotics and diagnostics, the AMR value of vaccines depends more on evidence of preventing infection and avoiding hospitalization costs.

  Risks

  Large-scale clinical trials, endpoint selection, regulatory acceptance, hospital willingness to purchase, and commercialization capabilities in LMICs are the main risks.

• Zydus Lifesciences / ZyVac TCV

  India vaccine and AMR value-chain-related asset

  Strengths

  Has more than 20 vaccine products, and ZyVac TCV has received WHO prequalification for active immunization against typhoid in people aged 6 months to 65 years.

  Weaknesses

  The product may not be marketed under an AMR asset label, so investors need to assess indirect value through reduced antibiotic use and resistance transmission.

  Comparison

  Compared with therapeutic antibiotics, typhoid conjugate vaccines express AMR relevance by reducing infections and empiric antibiotic use.

  Risks

  Public procurement, vaccination coverage, pricing, and funding sources in low-income markets affect commercial elasticity.

Key data

• Global AMR mortality burden in 2021About 1.2 million direct deaths and about 4.7 million associated deathsEstimated by the report based on Lancet GRAM 2024 analysis.
• Global AMR mortality outlook in 2050About 2 million direct deaths/year and about 8 million to 9 million associated deaths/yearReflects the long-term public health pressure of AMR.
• AMR economic costCould bring an additional US$1tn in healthcare costs by 2050; could cause annual GDP losses of US$2tn to US$3.4tn by 2030The report cites related World Bank estimates referenced by the WHO.
• India AMR exposureAverage annual deaths from bacterial infections of about 1.5 million to 1.6 million over the past five years, with AMR-related cases accounting for more than 60% and direct attribution of about 18% to 20%India is defined in the report as one of the world’s highest-exposure markets.
• India sepsis burdenIncidence of about 540 to 640 cases per 100,000 people, with mortality of about 25% to 30%The high sepsis pool reinforces the value of rapid diagnostics and anti-infective pathways.
• UK antibiotic stewardship effectTotal antibiotic items down about 8.2% and broad-spectrum prescriptions down about 18.9%Driven by prescribing-side financial incentives through the NHS England Quality Premium.
• UK subscription-style antibiotic paymentInitially up to about £10mn/product/year, with a budget of about £100mn/year after being made permanent in 2024For products such as Pfizer’s Zavicefta and Shionogi’s Fetcroja, with payment decoupled from volume.
• Sweden prescribing controlTarget of ≤250 outpatient prescriptions per 1,000 residents; outpatient antibiotic sales fell 15% during the program periodPrescriptions for children aged 0 to 4 fell 73% from 1992 to 2016.
• Japan pediatric antibiotic incentiveEligible first visits can receive an additional ¥800 fee; total prescriptions fell about 17% to 18% in the first yearOver four years, cumulative total prescriptions fell about 20%, while broad-spectrum drugs fell about 24%.
• Global antimicrobial pipeline90 antibacterial products in the clinical stage in 2025, down from 97 in 2023; among them, 15 are innovative and 5 cover at least one WHO critical priority pathogenThe report believes the pipeline remains thin.
• Potential AMR contribution from vaccinesIf existing vaccines reach 90% optimal coverage, they could avert about 100,000 AMR-related deaths, about US$900mn in hospitalization costs, and about 150 million defined daily doses of antibiotic useThe report cites related WHO estimates.
• Zaynich clinical and commercializationENHANCE-1 composite clinical cure and microbiological response was 89.0%, versus 68.4% for comparator meropenem; the report estimates sales in regulated markets could exceed US$1bn over the next 4 to 5 yearsWockhardt’s development cycle exceeded two decades, reflecting both high returns and high time costs.

Impact & implications

The report’s investment implication is that the AMR value chain should not be viewed only through traditional antibiotic sales, but through assets that can change prescribing behavior, shorten diagnosis time, reduce hospital stays, and prevent infections. Diagnostic companies can embed themselves into clinical workflows through same-visit decision-making and hospital infection pathways; vaccine companies can demonstrate health economic value by preventing infections and reducing antibiotic consumption; and novel antibiotic companies need policy-based payment, subscription models, or revenue guarantees to balance the conflict between R&D and restricted use. Investment opportunities in India stem from a high infection burden, demand for low-cost decentralized testing, domestic novel drug case studies, and vaccine manufacturing capabilities.

Risks

• Novel antibiotic R&D cycles are long and failure rates are high, while reserve use and antibiotic stewardship will constrain sales.
• Bacterial vaccine programs may fail due to antigen complexity, patient heterogeneity, and clinical endpoint requirements.
• The commercial value of rapid diagnostics depends on whether physicians actually change prescribing behavior based on the results, not just on obtaining test results.
• The Indian market requires low-cost, durable, and decentralized products, and pricing pressure may compress margins.
• AMR policy incentives and revenue guarantee models are still in pilot or early rollout stages across countries, and cross-market replication is uncertain.
• The report’s long-term mortality, cost, and sales estimates are subject to model and assumption uncertainty.
• Excessive pursuit of sterile environments may create long-term health risks related to the microbiome and immune system.

What to watch

• Whether the UK’s subscription-style antibiotic payment, Sweden’s revenue guarantee, and Japan’s prescribing incentives continue to expand.
• Subsequent WHO updates on the antimicrobial clinical pipeline, especially the number of truly innovative products covering critical priority pathogens.
• Zaynich’s launch timing in regulated markets, hospital access, sales ramp, and real-world efficacy.
• The execution strength of India’s NAP-AMR 2.0, ICMR surveillance network, Schedule H1, and Red Line campaign.
• Product validation, procurement, and primary-care deployment by Indian diagnostic companies such as Molbio, XCyton, HiMedia, and Haystack Analytics.
• Phase 3 progress of Bharat Biotech’s pre-surgical infection prevention vaccine and TB, Shigella, and Salmonella vaccine candidates.
• Whether platforms such as Zydus with WHO prequalification and LMIC manufacturing capabilities are re-rated by the market as AMR value-chain assets.
• Whether hospitals and payers are willing to pay a premium to avoid ICU stays, readmissions, and broad-spectrum antibiotic use.